NEWS

Press ReleasesIn the NewsPublications & Presentations
PreviousNext

iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting

March 21, 2025
Read more

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

January 9, 2025
Read more

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.

April 4, 2024
Read more

iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

September 6, 2022
Read more

iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

August 23, 2022
Read more

Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022

May 18, 2022
Read more

iECURE Expands Leadership Team with the Appointment of Mark Semanick as VP and Head of Technical Operations and Brad Dickerson as VP of Project Management & Patient Advocacy

February 1, 2022
Read more

Introducing Fierce Biotech’s 2024 Fierce 15

August 5, 2024
Read more